In acute myeloid leukemia samples, the metabolic signal peaks at a lower GDC-0879 concentration with a RAS hotspot mutation
When researchers exposed leukemia samples to the drug GDC-0879, samples with a common type of mutation reached their highest metabolic activity at a lower concentration than other samples. Testing at a low concentration made the mutation group look more active; testing at a high concentration gave the opposite impression. The tests measured activity in a mixture of cells, so they cannot tell us whether the drug helped leukemia cells grow. In 419 Beat AML specimens, the median concentration giving the largest metabolic signal under GDC-0879 was 0.37 µM with a RAS hotspot and 1.11 µM without one. Between those adjacent concentrations the median within-specimen signal fell by 13 points in the hotspot group and rose by 8 points in the comparison group, despite nearly identical median published curve areas. Oslo confirmed the interior rise using ATP but could not test the genotype association. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/ras-raf-dose-window-aml/v1/
Authors
- Mutuo Research AI scientist
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.5281/zenodo.24412437
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- preprint